SONN

Sonnet BioTherapeutics Stock Price

2.026
0.016 (0.8%)
Upgrade to Real-Time
Regular Market
2.026

Low
1.81

52 Week Range

High
7.89

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Sonnet BioTherapeutics Inc SONN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.016 0.8% 2.026 11:18:09
Open Price Low Price High Price Close Price Prev Close
2.03 2.01 2.0515 2.01
Bid Price Ask Price Spread News
2.02 2.04 0.02 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
238 74,915 $ 2.04 $ 152,590 839,844 1.81 - 7.89
Last Trade Time Type Quantity Stock Price Currency
11:18:09 250 $ 2.026 USD

Sonnet BioTherapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 34.80M 17.18M 15.98M $ - $ - -6.96 -0.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Sonnet BioTherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SONN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.062.17491.922.04361,653-0.034-1.65%
1 Month2.402.421.922.19473,519-0.374-15.58%
3 Months2.723.4151.812.56993,673-0.694-25.51%
6 Months2.803.4151.812.57884,292-0.774-27.64%
1 Year5.437.891.813.481,685,983-3.40-62.69%
3 Years6.2216.201.813.791,737,222-4.19-67.43%
5 Years6.2216.201.813.791,737,222-4.19-67.43%

Sonnet BioTherapeutics Description

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.


Your Recent History
NASDAQ
SONN
Sonnet Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.